you, Thank Charlie.
pleased are franchise Cushing We very quarter. with of performance our the syndrome last
taking Meanwhile, Cushing reduce year. practice revenue in There no has work prescribers expected, the left must nearly a them patients through patients, add the many of start gave do. But X,XXX did each are is reimbursement has our we every and temporary country Korlym United syndrome. continue we year because not was as There some Korlym pause first Endocrinology every with in growth it As patients expect quarter the to care to the There process, endocrinologists for we much since interrupted undergo at the of we insurance at Korlyms launch. patients cost. few reauthorization them and continue. to States
depend of with field are physicians specialists our quickly patients patients number hiring with to dedication work with effectively skill, how experience more the disease. we about exact sales of to from reach the and force will find the helping XX. this The to treating clinical physicians XX candidates size on To increasing required complex we and pace
XXXX Korlym trial glucocorticoid first, contribute receptor PR target modulating in short. causes for the Korlym additional it the pivotal is and at by binds however effect patients expect its not significantly fashioned. effects commercial use for in a affinity modulation that to A progesterone then treats beyond. We the of cortisol also cortisol receptor, makes its modulate clinical it activity board greatly short. Korlym Cushing can benefit just Korlym's off in business many cortisol, to shown the does specialists in for and PR to commercial our of limit GR the use. Korlym syndrome
fact, the In is the active ingredient medication the Korlym call same abortion as in in the pill.
age. experienced and Potassium is take is Korlym affinity PR many thickening different who causes in Korlym's also a important of endometrial the mechanism causes function By for the also women low significant portion medicine a hypokalemia. condition be bleeding low of vaginal their known it the regardless but manageable potassium a patients, potassium in and Korlym's of normal heart Hypokalemiais can treatment, particularly close is of is levels hypokalemia, XX% of discontinuation. the life cells leading of threatening. the cells muscle and pivotal nerve Korlym of requires monitoring one in causes prophylactic muscle patients trial often
off relacorilant thickening does successor not selective pill it relacorilant PR, by cause these target not bind cortisol it GR. not excess Unlike modulating does effects. vaginal planned or is relacorilant because Korlym, to Korlym, Our does cause endometrial and Korlym not works abortion it to is bleeding. Like activity at the
exhibited improvements commercial Korlym cause hypokalemia. weight advantages increased and mood unlike is not patients meaningful the life. well resistance, cortisol function, are and and and cognitive in endpoints trial's two does trial of loss, In medical These and was in major coagulopathy, liver significantly primary addition relacorilants tolerated. It Phase levels not function, a hypertension control variety quality of and endpoints glucose insulin including of secondary relacorilant
you at in no As adverse April see tab Past We can of instances by were these Association expected, results at Endocrinologists, were Events there events presented affinity poster website. there of and American meeting the of PR the our hypokalemia. caused the drug-induced Clinical our no of Investors annual
second improvements who is in the States, double-blind for a enrollment continue relacorilants patients metabolism Relacorilants Canada, in at or to receiving the XX XXX withdrawal hypertension switched in and X enter the study Each placebo. XX withdrawal in randomized relapse pleased of rest weeks. rate announce the of Phase Europe the randomized the during later XX-week relacorilant are receives GRACE's a have adrenal continuing underway plan comparing phase to this degree which endpoints Korlym study sites an call glucose Those trial, placebo. we which United are randomized primary prespecified Israel. These I'm have patients and a -- and trajectory. to those clinical a phase relacorilant syndrome the exhibit GRACE with planned indolent of patient patients in adenomas with GRACE patients that year. severe less disease to more trial Cushing begin and we
trial as this patients placebo. many expect study GRACE receiving the participants trial. half the as the the will participate GRACE rest relacorilant We study of in with sites, will participating and Many the enroll of this in approximately that
required this trial that It of is development important is to a part relacorilant program. a not note
been to syndrome meaningfully the on syndrome we etiology Cushing for That extensively studied NDA Relacorilant's said, Cushing of base contribute its not being of treatment. this to our expect expect We trial's and results results understanding GRACE. and to has
will our unfortunately of program. high solid suppresses tumors receptors and which kill survival harmful. the glucocorticoid prompting turn express this programmed tumor receptors, I cortisol effective including types, that cortisol known now chemotherapy have stimulation In rates. drugs with to apoptosis. cell correlates is tumors by glucocorticoid as Since ovarian levels death oncology pancreatic apoptosis, Many lower
chemotherapy down Abraxane cortisol and that I-II nab-paclitaxel, cortisols a to chemotherapeutic drug modulator trial a plus hypothesis relacorilant to Phase the its effect turn full adding will achieve taxane-based Our allow potential. Celgene's tested regimen anti-apoptotic
ASCO longer. growing year's The cancer of or for durable some XX tumors this in tumor cease two diseases patient cancer in with with Conference. ovarian longer at response, with pancreatic patients shrinkage patients weeks. trial weeks metastatic achieved X completely. notable. are The either shrinkage cancer this duration Tumor These control, striking from ovarian ovarian XX than patient advanced A X lesion the and disappeared or data exhibited with XX cancer pancreatic presented with results. of lasted of was meaning another XX their particularly patients weeks. XX We shrink for patients disease target in
of added All responded had to the prior patients including multiple lines these them when treatments was therapy of relacorilant or any with another was of paclitaxel therapy that nab- taxane undergone surprising.
website. available Past ASCO of Our is Investors tab our at poster the Events
nab-paclitaxel I-II Our ovarian XXX investigators that our Phase cancer. more we relacorilant advanced began we with patient plus justify definitive Phase results larger this patients in believe Earlier year, do trial II studies. of placebo-controlled as
with metastatic the path to FDA have approval addition, we'll cancer of that we III In guidance pancreatic the and in protocol seek trial nab-paclitaxel fastest patients indication. regarding for relacorilant in completed plus a writing Phase
clinical is an are designated by orphan briefly trial that I When drug for be exciting. relacorilant quote Orphan The Products comp Medicines described year-end. by results, Medicinal Committee results, to to direct pancreatic the treatment will patients, a recommended relacorilant expressed Our disease regimens. I've this taxane by as I Agency's from the opinion the European has partial control to the failed objective start for for is short. is demonstrated the previously quote some and achievement that This therapy. sensitivity cancer. treatment was in or of tumor potential responses the non-clinical This durable of restore despite
that agents preliminary the to these deprivation when by cancer the trials we dire if with considered significant drug benefit clinical shown Chicago in findings Investigators metastatic claim Sloan cells modulation it tumors different why can designation. orphan be The have Memorial as major that begins and with prostate, growth Deprivation androgen a at data may treatment. treated of larger cancers. mechanism our I-II growth COMP of the agree prostate supported advance the the by submitted are their androgens a standard Xtandi, and Androgen an is tumor which confirm treat constitute enzalutamide of initial stimulate cortisol. Pfizer's Phase by stimulated prostate Kettering in subsequent is such the of for of the University "We the patients purpose Cortisol will sponsor treatment
of of cortisol University Our at it controlled at will plus the Investigators Chicago trials, leading hypothesis a modulator escape standing which to with originates investigators hypothesis plus examining this adding to deprivation are Xtandi. one androgen other block relacorilant University Phase tumor II therapy the Chicago. route. Korlym Is this testing the and
we'll castration-resistant as as with of our Xtandi trial by University the data proprietary cortisol well formerly are cancer, trial with trial CORTXXXXXX data and exicorilant conducting combined that led from evaluate to dose the treat a from modulator is prostate being finding patients of selective We Chicago.
bipolar We die gain of prescribed caused disorders. diseases. this and reduce controlled placebo In weight whether treat metabolic antipsychotic for medications gain it which on status they're to of Xb a cardiovascular and in widespread and some which healthy FDA abortion another by no weight test determine disease. mifepristone, in antipsychotic our metabolic began schizophrenia including effects, approved the caused shown and olanzapine most effective, for NASH, shorten conducted cortisol the to to gain Phase medication the let Investigators lives are program. the as play model development it these but anti-psychotic serious on trial steatohepatitis metabolic antipsychotic a mifepristone of non-alcoholic we olanzapine. medications treatment a modulation whom as there have hyperglycemia effects patients, of will available is may we significantly treatments. patients in conclude treating rely with and discussion illnesses from studies role from risperidone. steps pill of prevented medication disorder our us subjects I miricorilant in the next by such for me hyperlipidemia dosing Pre-clinical common advancing clinical program a April or side appropriate data background the once as Weight are provide millions disorders two medications the commonly attenuates side Unfortunately trial
a it our candidate is trial healthy selective a relacorilant receptor two progesterone placebo receive for miricorilant has because Like viable subjects and XX cortisol weeks. is either or current activity. no it modulator. Miricorilant In olanzapine
trial's change primary endpoint the in Although weight. is
is studies were I Its goal. in is well from Pharmacodynamics This powerful. very first We of potential results activity. know tolerated. have more study our Phase miricorilant a We animal its that fundamental trial miricorilant
metabolic for study about properties begin learn its is people. Our this objective to to in
recent this We to our placebo-controlled reversal also a induced the we long-standing double, Phase later patients will will double-blind, XXXX miricorilant II Later have optimize initiate have a year, gain. after results weight II weight begin we also trial complete, formulation In will antipsychotic in and induced is trial program we with Phase a year. will this antipsychotic gain. of
serious NASH, of that affects Now, animal to appears disorder animal conditions, of It NASH in by liver fatty conditions precursor these a even syndrome. characterized in more If with is I'll miricorilant these potent United cirrhosis. fibrosis. the say another a models reverse millions patients is and words about inflammation a person is few metabolic Cushing States. models liver In in is fatty and to disease people potent. of
to [indiscernible] initiate at next Phase placebo-controlled double-blind, in with expect We NASH trial, year. a patients II
our XXXX to We revenue for an million excellent our recap, of business had syndrome quarter. million reaffirm guidance XXXX. Cushing $XXX To $XXX
commercial We trial to enroll we which III in results less size are trial our force, a year. begin of Relacorilants Phase field to significantly begin syndrome next enabling increasing the NDA severe patients should Separately, sales will contribute double-blind GRACE with continues later to our placebo-controlled patients. Cushing this year.
from important We therapy prior for data pancreatic patients a of our will on presented disease durable ovarian oncology and that control advances continue to of in metastatic trial use make what program. We at be Phase cancer I-II year. population showed lines including with a prior have this taxane. multiple and ASCO data striking received expected is The
plus Abraxane enrolling patient-controlled actively trial relacorilant cancer. are We subjects in II in Phase XXX ovarian
year. cancer expect with We trial pancreatic patients III this later begin to Phase in metastatic a
exicorilant and the as Chicago trial trial at University data of relacorilant. enzalutamide plus Our the with led being by is generate Korlym investigators of continues to
Our our begin healthy to this gain is the being metabolic milestone, tested and XXXX. lead induced to gain and subjects it two another trials be program two induced attenuation for one Phase, an of important compound miricorilant antipsychotic one weight and antipsychotic in year weight later begin in will conducted expect achieved
Phase patients a to II start trial treat We to NASH also next with year. plan miricorilant of
questions. for here stop I'll
